6 Citations (Scopus)

Abstract

Parkinson disease psychosis (PDP) is a common phenomenon in Parkinson disease (PD) patients treated with dopaminergic drugs, and is associated with high morbidity and mortality. It also correlates with depression and dementia, and can contribute to considerable caregiver stress and burnout. While symptoms can be relieved by decreasing doses or number of anti-PD medications, this may lead to an unacceptable worsening of motor function. When general medical or psychiatric conditions have been ruled out, and decreasing dopaminergic agents is not effective in treating psychosis, therapies include atypical antipsychotics, primarily clozapine and quetiapine. Of these, clozapine is effective but is associated with a poor side-effect profile and the necessity for frequent blood draws. Clinicians prefer quetiapine for its theoretically better safety profile, although there is no evidence for efficacy in treating psychosis. All atypical antipsychotics are associated with increased mortality in this patient population. Cholinesterase inhibitors can ameliorate psychosis symptoms. The serotonin 5-HT2A receptor inverse agonist pimavanserin was recently approved by the US FDA for the treatment of PDP and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalDrugs and Aging
DOIs
StateAccepted/In press - Nov 9 2016

Fingerprint

Psychotic Disorders
Parkinson Disease
Antipsychotic Agents
Dopamine Agents
Clozapine
Serotonin 5-HT2 Receptor Agonists
Mortality
Cholinesterase Inhibitors
Caregivers
Psychiatry
Dementia
Therapeutics
Depression
Morbidity
Safety
Population
Quetiapine Fumarate

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology (medical)

Cite this

@article{4730d411a97445b2a914c11e54f79119,
title = "Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management",
abstract = "Parkinson disease psychosis (PDP) is a common phenomenon in Parkinson disease (PD) patients treated with dopaminergic drugs, and is associated with high morbidity and mortality. It also correlates with depression and dementia, and can contribute to considerable caregiver stress and burnout. While symptoms can be relieved by decreasing doses or number of anti-PD medications, this may lead to an unacceptable worsening of motor function. When general medical or psychiatric conditions have been ruled out, and decreasing dopaminergic agents is not effective in treating psychosis, therapies include atypical antipsychotics, primarily clozapine and quetiapine. Of these, clozapine is effective but is associated with a poor side-effect profile and the necessity for frequent blood draws. Clinicians prefer quetiapine for its theoretically better safety profile, although there is no evidence for efficacy in treating psychosis. All atypical antipsychotics are associated with increased mortality in this patient population. Cholinesterase inhibitors can ameliorate psychosis symptoms. The serotonin 5-HT2A receptor inverse agonist pimavanserin was recently approved by the US FDA for the treatment of PDP and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.",
author = "Niyatee Samudra and Neepa Patel and Womack, {Kyle B.} and Pravin Khemani and Shilpa Chitnis",
year = "2016",
month = "11",
day = "9",
doi = "10.1007/s40266-016-0416-8",
language = "English (US)",
pages = "1--9",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Psychosis in Parkinson Disease

T2 - A Review of Etiology, Phenomenology, and Management

AU - Samudra, Niyatee

AU - Patel, Neepa

AU - Womack, Kyle B.

AU - Khemani, Pravin

AU - Chitnis, Shilpa

PY - 2016/11/9

Y1 - 2016/11/9

N2 - Parkinson disease psychosis (PDP) is a common phenomenon in Parkinson disease (PD) patients treated with dopaminergic drugs, and is associated with high morbidity and mortality. It also correlates with depression and dementia, and can contribute to considerable caregiver stress and burnout. While symptoms can be relieved by decreasing doses or number of anti-PD medications, this may lead to an unacceptable worsening of motor function. When general medical or psychiatric conditions have been ruled out, and decreasing dopaminergic agents is not effective in treating psychosis, therapies include atypical antipsychotics, primarily clozapine and quetiapine. Of these, clozapine is effective but is associated with a poor side-effect profile and the necessity for frequent blood draws. Clinicians prefer quetiapine for its theoretically better safety profile, although there is no evidence for efficacy in treating psychosis. All atypical antipsychotics are associated with increased mortality in this patient population. Cholinesterase inhibitors can ameliorate psychosis symptoms. The serotonin 5-HT2A receptor inverse agonist pimavanserin was recently approved by the US FDA for the treatment of PDP and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.

AB - Parkinson disease psychosis (PDP) is a common phenomenon in Parkinson disease (PD) patients treated with dopaminergic drugs, and is associated with high morbidity and mortality. It also correlates with depression and dementia, and can contribute to considerable caregiver stress and burnout. While symptoms can be relieved by decreasing doses or number of anti-PD medications, this may lead to an unacceptable worsening of motor function. When general medical or psychiatric conditions have been ruled out, and decreasing dopaminergic agents is not effective in treating psychosis, therapies include atypical antipsychotics, primarily clozapine and quetiapine. Of these, clozapine is effective but is associated with a poor side-effect profile and the necessity for frequent blood draws. Clinicians prefer quetiapine for its theoretically better safety profile, although there is no evidence for efficacy in treating psychosis. All atypical antipsychotics are associated with increased mortality in this patient population. Cholinesterase inhibitors can ameliorate psychosis symptoms. The serotonin 5-HT2A receptor inverse agonist pimavanserin was recently approved by the US FDA for the treatment of PDP and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.

UR - http://www.scopus.com/inward/record.url?scp=84994453257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994453257&partnerID=8YFLogxK

U2 - 10.1007/s40266-016-0416-8

DO - 10.1007/s40266-016-0416-8

M3 - Article

SP - 1

EP - 9

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

ER -